Progenics Pharma (PGNX) Tops Q4 EPS by 4c
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.